Welcome visitor Log In - or - Register
0 items /
View Cart
Check Out
four ways
Quick Search:
RGX-104 is an oral, selective LXR (Liver-X Nuclear Hormone Receptor) agonist, and a first-in-class immunotherapy agent. It activates the expression of the ApoE gene and reverses the immunosuppressive effects of cancer by targeting the LXR/ApoE pathway that regulates the innate immune response to cancer. This next-generation therapy has two key effects on the innate immune system that drive tumor immunity: it depletes myeloid-derived suppressor cells (MDSCs) and stimulates dendritic cells (DCs). MDSCs block the ability of T cells to become active, while stimulated DCs are required for proper activation (priming) of T cells. It is currently under evaluation either as monotherapy or in combination with approved therapies, such as immune check-point inhibitors, to treat patients with refractory solid tumors (refs 1, 2).
Catalog NO: CT-RGX104
Synonym: RGX104
CAS NO: 610318-54-2
Mol. Formula: C34H33ClF3NO3
MW: 596.1
** The Optically Pure Source. in vivo Quality Material. >99% pure by Achiral and Chiral HPLCs (All Quality Controls are attached). Anhydrous, salt-free, validated by a spot-on Quantitative Elemental Analysis. Bulk stock! Prompt.